Cell-type Specific Interrogation of Variant Function in Alzheimer's Disease
Cell-type Specific Interrogation of Variant Function in Alzheimer's Disease
批准号:
10749582
负责人:
Marielle Louise Bond
金额:
$3.91万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-04 至 2026-08-03
关键词:
ATAC-seqAffectAllelesAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAstrocytesAutomobile DrivingAutopsyBindingBiologicalBiological AssayCRISPR interferenceCRISPR/Cas technologyCell LineCellsClustered Regularly Interspaced Short Palindromic RepeatsData SetDementiaDevelopmentDiseaseEnhancersEtiologyExhibitsFutureGene Expression RegulationGenesGeneticGenetic TranscriptionGenomeGenomic SegmentGenomicsGoalsHi-CHumanInheritedLinkLinkage DisequilibriumMapsMethodsMicrogliaModelingMolecularNeurodegenerative DisordersNeuronsNucleic Acid Regulatory SequencesPersonsPhenotypePlayProtocols documentationRegulatory ElementReporterResearchRestRiskSpecificityStimulusTechniquesTechnologyTherapeuticUntranslated RNAValidationVariantWorkbrain cellbrain tissuecausal variantcell typedesigndrug developmentexperimental studyfallsgene productgenetic variantgenome wide association studygenomic datainduced pluripotent stem cellmultiple omicspromoterresearch and developmentresponserisk variantstem cell differentiationtargeted treatmenttherapeutic candidatetherapeutic developmenttooltranscription factortranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Alzheimer’s Disease (AD) affects over 26 million people worldwide, yet the treatment options are limited. This
is in large part due to the unclear molecular mechanisms underlying AD. Genome-wide association studies
(GWAS) have identified genomic regions that are associated with AD, but determining the exact causal variants
and genes remains a major challenge. Recent developments in high throughput genomic technologies have
incredible potential to functionally characterize these causal features, but must be applied to the correct cell
types. Neurons, astrocytes, and microglia are all thought to play key roles in the etiology of AD but obtaining
viable primary human brain cells for these experiments is understandably very difficult. Therefore, recent
protocols to rapidly differentiate human induced pluripotent stem cells into various brain cell types offer great
promise as tools to decipher the genetic basis of AD and guide future therapeutic efforts.
The goal of this project is to identify which AD risk variants alter transcriptional regulatory capacity in human
brain cells and to map them to the genes they regulate. To understand which variants are functional in microglia,
astrocytes, and neurons, I will perform massively parallel reporter assays in human induced pluripotent stem
cells (hiPSCs) differentiated into each cell type (Aim 1). To identify AD risk genes, I will use publicly available
Hi-C, ATAC-seq, and RNA-seq in hiPSC-derived microglia, astrocytes, and neurons to link variants to genes
(Aim 2A). I will functionally validate a selection of putative variant-gene pairs with CRISPR inhibition (Aim 2B).
The results of this work will identify cell-type specific causal variants, and the genes that they regulate. This
will have a positive impact because understanding exactly which genes are involved in which cell types in AD
will elucidate the molecular mechanisms of the disease etiology. The genes identified in this study can act as
targets for future studies and candidates for therapeutic design.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金